Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00315276 · ClinicalTrials.gov registry record · Phase 2
Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD
A Phase 2 study of Attention Deficit Hyperactivity Disorder and ADHD, sponsored by Cephalon.
- Completed
- Registry status
- Phase 2
- Development phase
- 370
- Enrollment target
- 18
- Study locations
NCT00315276: Completed Phase 2 study of Attention Deficit Hyperactivity Disorder and ADHD, sponsored by Cephalon.
NCT00315276 is a Phase 2 study of Attention Deficit Hyperactivity Disorder and ADHD that has completed, run by Cephalon. The registered enrollment target is 370 participants, above the 213-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (74% higher). The trial reports 18 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00315276, a Phase 2 study of Attention Deficit Hyperactivity Disorder and ADHD, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 370 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of the study is to evaluate the efficacy and safety of modafinil administered once daily for 9 weeks at doses of 255, 340, 425, and 510 mg as treatment for adults with ADHD.
Conditions Studied
Interventions
- DRUG Modafinil
Study Locations (18)
California
- Bay Area Research Institute - Lafayette
- Pharmacology Research Institute - Northridge
- Peninsula Research Associates - Rolling Hills Estates
- UCSD Medical Center - San Diego
Arkansas
- Neurology Clinical Study Centers, LLC - Little Rock
Florida
- Clinical Neuroscience Solution, Inc. - Orlando
Illinois
- University of Illinois - Chicago
Kentucky
- Michael J. Reiser, MD, LLC - Lexington
Maryland
- Adult ADD Center of Maryland - Lutherville
Massachusetts
- Massachusetts General Hospital - Cambridge
Michigan
- Rochester Center for Behavioral Medicine - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
What the finished NCT00315276 record still lists
NCT00315276 is an interventional study that assigns participants to a tested intervention. The registered 370 participants enrollment target is mid-sized for trials with a published cap, above the 213-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (74% higher).
The record links to 2 conditions, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which Modafinil is the first listed.
NCT00315276 lists 18 locations in 15 states (California, Arkansas, Florida).
Frequently Asked Questions
What is clinical trial NCT00315276 about?
NCT00315276 is a clinical study titled "Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD". The purpose of the study is to evaluate the efficacy and safety of modafinil administered once daily for 9 weeks at doses of 255, 340, 425, and 510 mg as treatment for adults with ADHD.
What is the current status of trial NCT00315276?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 370 participants. The study started on 2006-05. Estimated completion is 2007-01.
What conditions does trial NCT00315276 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder, ADHD.
What interventions are being tested in trial NCT00315276?
The interventions under investigation include: Modafinil (DRUG).
Who is sponsoring clinical trial NCT00315276?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00315276 being conducted?
This trial has 18 study locations across Arkansas, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00315276's enrollment target sits among peer trials
370 13th of 102 higher than 90 of 102 other Attention Deficit Hyperactivity Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Acute Effects of Stimulant Medication in College Students With ADHD
RECRUITING · Phase 2
-
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
RECRUITING · Phase 2
-
Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)
COMPLETED · Phase 2
-
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
COMPLETED · Phase 2
-
Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- NCT04284436 · 370 participants · NA
Study in Parkinson Disease of Exercise
- NCT05026749 · 370 participants · Phase 3
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
- NCT05125016 · 370 participants · Phase 1
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia